Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
dunno, depends on momo and what momo players see.
i placed a few click to reads in ibox.
tomorrow im coming in.. bets go the conference call being positive
looks like the float is locked up any buying pressure sends it
at yhoo...pinks not much;
Share Statistics
Avg Vol (3 month)3: 242,783
Avg Vol (10 day)3: 78,829
http://finance.yahoo.com/q/ks?s=DDSSF.PK+Key+Statistics
Shares Outstanding5: 71.57M
Float: 71.11M
Headlines Filter Headlines.•Labopharm to host conference call Thursday, August 4, 2011 at 8:30 A.M. (ET)CNW Group(Thu, Jul 28)
http://finance.yahoo.com/q?s=ddssf.pk&ql=1
looking it up;;;
doing from memory...if 8-6 then ya right on target.
trades thin, whats the SS here?
i read 8/6.. thursday?
hey man, markets getting pounded and yet this trades steady, can this see 1 or higher?
i can buy about 5k shares
i haven't heard of the milestone payment yet. have you? anyone?
Labopharm (QB) (DDSSF) 0.2271 ? 0.0 (0.00%) Volume: 35,756 @ 3:07:43 PM ET
Bid Ask Day's Range
0.2271 0.244 0.219 - 0.245
DDSSF Detailed Quote
conference 8-4-11 ,
hi A and to all.
looking to buy tomorrow, this one looks like it can run much higher,a little volume and she pops...
http://ih.advfn.com/p.php?pid=trades&symbol=DDSSF
small sells not much buying going on
when is the conference call.... this week?
I will sell PTN tomorrow at a small loss and invest in this bio instead... this company is on the right track..
charts holding strong despite market meltdown
no nothing so far waiting for big pop hope we will get some
this stock also plays on the TSX..looks good for more..focus on that market things are strong in Canada
yes and yes with good following.
sheff is a genius!
even sheff is taking a beating..... i think CYCC will R/S soon imo
$heff
Share
Wednesday, July 27, 2011 2:10:37 PM
Re: None Post # of 46434
OT: Folks..lots of red in my portfolio here today. I am down on both CYCC & PATH. Even on CLSN now. Lost on DVAX when I was away. Still holding both CYCC & PATH as well as CLSN. ALXA will come back as well. I get annoyed with companies that set investors up with target dates on NDA's & then don't hit them. TLON was a perfect example of that. At least ALXA told investors that they had a specific date in mind of Aug 8th. That is good! May re-enter at a future date.
i think a winner here back to one dollar or more.
maybe $heff getzzz on it.
nice profitable small bio here! product sales are increasing year over year.
i think it can. conference call will tell some stories. looks like restructure will work.
cost lot of money to keep drugs in pipeleine.
i added new stuff to ibox.
looks like this one can run mick.
yes on $10mil. sales as reads. doesn't say how much milestone payment will be.
i hope not is sales agreement.
i dressed up ibox some.
??? "Labopharm will receive a royalty of 5% on net sales of OLEPTROTM in the United States in excess of US$10 million in any calendar quarter. Net sales of OLEPTROTM in the United States for the most recent quarter ended March 31, 2011 were $908,000. "
So are they saying the company gets nothing until sales are 10X what the are today???
Press Release; 7/28/2011
Labopharm to host conference call Thursday, August 4, 2011 at 8:30 A.M. (ET)
LAVAL, QC, Jul 28, 2011, 2011 (Canada NewsWire via COMTEX) --
- Management to discuss second quarter 2011 financial results -
Labopharm Inc. (TSX: DDS) (NASDAQ: DDSS) today announced that it will host a conference call on Thursday, August 4, 2011 at 8:30 a.m. (ET) to discuss its second quarter 2011 financial results. Labopharm will report its second quarter 2011 financial results via news release at approximately 7:00 a.m. (ET) the same day.
To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Thursday, August 11, 2011 at midnight. To access the archived conference call, dial 416-849-0833 or 1-855-859-2056 and enter the reservation number 87032649.
A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.
About Labopharm Inc.
Labopharm is focused on realizing value from its commercialized products and creating additional value by leveraging its emerging technology platforms to develop increasingly differentiated products. For more information, visit http://www.labopharm.com.
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/July2011/28/c7965.html
SOURCE: Labopharm Inc.
At The Equicom Group Lawrence Chamberlain Media and Investor Relations Tel: (416)
815-0700 ext. 257 lchamberlain@equicomgroup.com French: Joe Racanelli Tel: (514)
844-7997 jracanelli@equicomgroup.com
Press Release; 7/29/2011
Labopharm and Angelini to Restructure Partnership
LAVAL, QC, Jul 29, 2011, 2011 (Canada NewsWire via COMTEX) --
- Labopharm to Transfer OLEPTROTM to Angelini for U.S., Canada and Other Countries Globally in Exchange for a Royalty -
Labopharm Inc. (TSX: DDS) and Gruppo Angelini (Angelini), its partner in the joint venture established by the two companies to commercialize OLEPTROTM in the U.S., today announced that they have entered into an agreement to restructure their partnership. Labopharm and Angelini have agreed to terminate their existing agreements and Labopharm will grant Angelini an exclusive license and rights related to OLEPTROTM in the U.S., Canada and other countries globally in exchange for a royalty on product sales.
As a result of the partnership restructuring, Labopharm will no longer be responsible to fund Angelini Labopharm LLC (Angelini Labopharm), the joint venture established by the two companies to commercialize OLEPTROTM in the United States. OLEPTROTM will continue to be available in the United States.
"We believe that OLEPTROTM is a valuable product for the treatment of depression and the restructured partnership provides us with the opportunity to benefit financially from the success of this product while enabling us to further preserve capital as we continue to progress with the strategic review process," said Mark A. D'Souza, President and Chief Executive Officer, Labopharm Inc.
Under the terms of the new agreement, the two companies will terminate the existing joint venture agreement and ancillary agreements established in May 2010 and dismantle the joint venture such that Labopharm will transfer its 50% ownership interest in Angelini Labopharm to Angelini.
Labopharm will receive a royalty of 5% on net sales of OLEPTROTM in the United States in excess of US$10 million in any calendar quarter. Net sales of OLEPTROTM in the United States for the most recent quarter ended March 31, 2011 were $908,000.
In addition, Labopharm will receive a royalty of 5% on net sales of OLEPTROTM in those countries for which it is granting rights to Angelini, including Canada, where OLEPTROTM has received regulatory approval, and other countries globally, for which Angelini does not already have the commercialization rights.
As a result of the restructured agreement, Angelini would be the sole owner of all commercialization rights related to OLEPTROTM globally.
As part of the restructuring of the joint venture, Labopharm will grant to Angelini an exclusive license and rights to commercialize Labopharm's twice-daily acetaminophen product in all European Union countries, Turkey, Georgia and the Commonwealth of Independent States (Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine, Uzbekistan).
Labopharm will receive a royalty of 5% on net sales of its twice-daily acetaminophen product in the aforementioned countries. Labopharm will also receive milestone payments upon signing of the agreement and the achievement of an agreed sales milestone.
All transactions are expected to close in the coming weeks and are subject to closing conditions customary to such transactions.
About OLEPTROTM
OLEPTROTM is a novel once-daily formulation of trazodone.
OLEPTROTM is intended to provide a new treatment option for patients with major depressive disorder (MDD) with the convenience of once-daily dosing and a differentiated side-effect profile. OLEPTROTM has received regulatory approval in the United States and Canada and was launched in the U.S. in 2010.
About Labopharm Inc.
Labopharm is focused on realizing value from its commercialized products and creating additional value by leveraging its emerging technology platforms to develop increasingly differentiated products. For more information, visit www.labopharm.com.
This press release contains forward-looking statements within the meaning of applicable Canadian Securities legislation, including, statements concerning the restructuring of the joint venture with Gruppo Angelini and statements concerning OLEPTROTM for the United States, Canada and other countries globally, which reflect Labopharm's current expectations regarding future events. These forward-looking statements involve risks and uncertainties, many of which are beyond Labopharm's control.
Actual events could differ materially from those projected herein and depend on a number of risks and uncertainties, including risks related to Labopharm's ability to complete partnering transactions and the terms of any such collaboration, if any, risks related to the market acceptance of Labopharm's products and the speed of adoption by clinicians, risks related to intellectual property protection and potential infringement of third-party rights, risks related to research and development of pharmaceutical products and regulatory approvals, and risks associated with intense competition in the pharmaceutical industry generally.
For additional disclosure regarding these and other risks faced by Labopharm Inc., see the disclosure contained in its public filings with the Canadian Securities Administrators (CSA), available on the Investor Relations section of Labopharm's website at www.labopharm.com and on the CSA's website at www.sedar.com. Investors are cautioned not to place undue reliance on these forward-looking statements.
Unless required by law, Labopharm undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise.
OLEPTROTM is a trademark of Labopharm Inc.
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/July2011/29/c8383.html
SOURCE: Labopharm Inc.
At The Equicom Group Lawrence Chamberlain Media and Investor Relations Tel: (416)
815-0700 ext. 257 lchamberlain@equicomgroup.com French: Joe Racanelli Tel: (514)
844-7997 jracanelli@equicomgroup.com
hi and to all. any updates?
this one is a good company imo. don't see why but trader's pay what one is worth.
People must think that the CC will be better than the last years worth of CC`s (IMO) WE will never be inside the FDA approve or not news ahead of time.
•Labopharm to host conference call Thursday, August 4, 2011 at 8:30 A.M. (ET)CNW Group(Thu, Jul 28)
Search resultsDDSSF - Labopharm Inc Stock quote - CNNMoney.com
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited ...
money.cnn.com/quote/?quote.html?symb=DDSS - Cached
DDSSF - What does DDSSF stand for? Acronyms and abbreviations ...
Acronym Definition; DDSSF: Dilute Double-Shell Slurry Feed
acronyms.thefreedictionary.com/DDSSF - Cached
DDSSF stock quote - Labopharm Inc. stock price - NASDAQ.com
Stock quote for Labopharm Inc. (DDSSF) - Get stock prices, stock quotes, stock charts, summarized market data, and company-specific research tools for Labopharm Inc ...
www.nasdaq.com/asp/?SummaryQuote.asp?symbol=DDSSF&... - Cached
DDSSF - Labopharm Inc Forecast - CNNMoney.com
The 3 analysts offering 12-month price forecasts for Labopharm Inc have a median target of 0.47, with a high estimate of 0.77 and a low estimate of 0.41.
money.cnn.com/quote/forecast/?forecast.html?symb=DDSS - Cached
DDSSF: LABOPHARM INC Stock Quote
Find DDSSF stock information including current LABOPHARM INC stock quote, stock price, and more.
www.dailyfinance.com/quotes/labopharm-?inc/ddssf/nao - Cached
DDSSF.PK: Summary for LABOPHARM INC.- Yahoo! Finance
View the basic DDSSF.PK stock chart on Yahoo! Finance. Change the date range, chart type and compare LABOPHARM INC. against other companies.
finance.yahoo.com/q?s=DDSSF.PK - Cached
http://search.yahoo.com/search?p=ddssf
have you heard if f.d.a. is getting closer to o.k. the drug here?
http://www.labopharm.com/
http://finance.yahoo.com/q/h?s=DDSS
http://www.labopharm.com/default.aspx?id=153
Labopharm, Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers a once-daily formulation of the pain-killer, tramadol to treat patients with moderate to severe pain in the United States, Europe, Mexico, Latin America, and the Caribbean. The company conducts Phase III clinical studies for once-daily formulations of Trazodone, an antidepressant; Phase I clinical studies for Tramadol combination products to meter the dispersion of two active ingredients for clinically beneficial interaction between the drugs; Phase I clinical studies for abuse resistant formulations of an opioid drug to provide patient safety; and Phase I clinical studies for anti-inflammatory products. It also develops a once-daily formulation of betahistine, an oral histamine analogue, for the treatment of the symptoms related to Meniere's disease, a disorder characterized by recurrent vertigo and hearing loss; and DDS-2001, an undisclosed formulation in Phase I studies. Labopharm's products are based on Contramid platform, a drug delivery technology that meters the release of drugs from orally administered solid dosage forms, such as tablets. In addition, it develops polymeric nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs, as well as for developing intravenous and oral formulation product candidates. The company was founded in 1990. It was formerly known as Centre de recherche appliquee pharmaceutique CRAP, inc. and changed its name to Labopharm, Inc. in 1994. Labopharm, Inc. is headquartered in Laval, Canada
the drug is approved in italy. not in u.s.a. so far. f,d,a, not easy to deal with.
Labopharm (QB) (DDSSF)
0.2505 ? 0.0655 (35.41%)
Volume: 165,976 @ 10:46:08 AM ET
Bid Ask Day's Range
0.2211 0.25 0.1831 - 0.261
DDSSF Detailed Quote
Bottom in and hope it can grow income this quarter,any rumors ?
(IMO) It will trade on the TO.exchange and pinks in the states,the market cap is so low that even a RS would not be enough to keep it`s nas listing.
Pinky or RS which one is worse? Looking cheap,but in order to state in NASDQ need RS and if RS is announce,PPS will drop, if states in Pinky,big institution will overlook DDSS,JIMO,GLTA. Waiting on the sideline...
Followers
|
24
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1202
|
Created
|
06/01/07
|
Type
|
Free
|
Moderators |
Board of Directors
Santo J. Costa 3
Mark D'Souza
Julia Brown 1
Richard J. MacKay 3
Frédéric Porte 2
Jacques Roy 1,2
Rachel R. Selisker 1,2
Officers
Mark D'Souza
President and CEO
Damon Smith
Senior Vice-President, Research and Development
Gregory M.C. Orleski
Vice-President, Business Development
Jeffrey M. Dayno, M.D.
Chief Medical Officer
Sylvain Guénette, CA
Chief Financial Officer
Sybil Skinner-Robertson
Vice-president, Regulatory Affairs
Labopharm, Inc.
(Head Office)
480 Armand-Frappier Blvd.
Laval, Quebec, H7V 4B4
Canada
Tel: (450) 686-0207
Fax: (450) 686-9141
Labopharm USA, Inc.
202 Carnegie Center,
Suite 204
Princeton, NJ 08540
United States
Tel: (609) 454-0207
Fax: (609) 454-0202
Labopharm Europe Limited
5, The Seapoint Building
44 Clontarf Road
Dublin 3, Ireland
Tel:+353 (0)1 854 0140
Fax:+353 (0)1 854 0144
Labopharm, Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers a once-daily formulation of the pain-killer, tramadol to treat patients with moderate to severe pain in the United States, Europe, Mexico, Latin America, and the Caribbean. The company conducts Phase III clinical studies for once-daily formulations of Trazodone, an antidepressant; Phase I clinical studies for Tramadol combination products to meter the dispersion of two active ingredients for clinically beneficial interaction between the drugs;
Phase I clinical studies for abuse resistant formulations of an opioid drug to provide patient safety; and Phase I clinical studies for anti-inflammatory products. It also develops a once-daily formulation of betahistine, an oral histamine analogue, for the treatment of the symptoms related to Meniere's disease, a disorder characterized by recurrent vertigo and hearing loss; and DDS-2001, an undisclosed formulation in Phase I studies. Labopharm's products are based on Contramid platform, a drug delivery technology that meters the release of drugs from orally administered solid dosage forms, such as tablets. In addition, it develops polymeric nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs, as well as for developing intravenous and oral formulation product candidates. The company was founded in 1990. It was formerly known as Centre de recherche appliquee pharmaceutique CRAP, inc. and changed its name to Labopharm, Inc. in 1994. Labopharm, Inc. is headquartered in Laval, Canada.
overview
http://finance.yahoo.com/q/ks?s=DDSSF.PK+Key+Statistics
Shares Outstanding5: 71.57M
Float: 71.11M
6-K | Jul 12, 2011 | Jul 12, 2011 | 10.6 KB | PDF RTF HTML |
15-12G | Jul 12, 2011 | 10.3 KB | PDF RTF HTML XLS |
FORM 6-K
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8038056
http://rttnews.com/ArticleView.aspx?Id=1184469&pageNum=2978_5599_8156_8314_1
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |